Cannabinoid Pipeline Analysis Report 2026

Report Coverage

The Cannabinoid Pipeline Analysis Report by Expert Market Research gives comprehensive insights into Cannabinoid therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Cannabinoid. The Cannabinoid report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The Cannabinoid pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with Cannabinoid treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to Cannabinoid.

Read more about this report - Request a Free Sample

Cannabinoid Pipeline Outlook

The cannabinoid pipeline continues to expand as regulatory support and scientific research accelerate the development of novel cannabinoid-based therapeutics across multiple therapeutic areas. In April 2026, the U.S. Department of Justice announced that FDA-approved marijuana products would be placed in Schedule III, a milestone expected to facilitate clinical research and innovation. Cannabinoid pipeline analysis by Expert Market Research highlights growing investment in advanced cannabinoid formulations, precision therapeutics, and expanded clinical programs targeting neurological disorders, chronic pain, oncology, and other unmet medical needs.

Cannabinoid Epidemiology

Cannabinoids are being increasingly investigated for neurological disorders, chronic pain, epilepsy, oncology supportive care, and other conditions, reflecting expanding therapeutic interest. Globally, cannabis remains the most widely used illicit drug, with an estimated 256 million people (4.8% of those aged 1-64) using cannabis in 2024, according to the UNODC. A 2024 systematic review also found a pooled cannabis use prevalence of 12.0% in countries where cannabis is legalized, compared with 5.4% in countries without legalization, highlighting the influence of regulatory policies on use patterns.

Cannabinoid – Pipeline Therapeutic Assessment

Cannabinoid Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase I and II covers a major share of the total cannabinoid clinical trials. The clinical trial distribution comprises Early Phase I (5.88%), Phase I (41.18%), Phase II (41.18%), and Phase III (11.76%). This distribution highlights a strong focus on early- and mid-stage clinical development, reflecting sustained research efforts to advance novel cannabinoid-based therapies toward commercialization.

Cannabinoid Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the Cannabinoid pipeline analysis include small molecules, monoclonal antibodies, and gene therapies. The Cannabinoid report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for cannabinoid. For instance, in July 2024, The FDA and FTC issued warning letters against companies marketing illegal Delta-8 THC products, strengthening regulatory oversight, protecting consumers, and encouraging development of compliant cannabinoid therapeutics.

Cannabinoid Clinical Trials – Key Players

The EMR report for the Cannabinoid pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed Cannabinoid therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in Cannabinoid clinical trials:

• Incannex Healthcare Ltd
• Avextra Pharma GmbH
• SocraMetrics GmbH
• Jazz Pharmaceuticals
• Terra Mater Botanicals Pty Ltd
• GW Pharmaceuticals Ltd
• Delphian Therapeutics
• Revive Therapeutics
• Cannaflos GmbH
• MAKScientific

Cannabinoid – Emerging Drugs Profile

Key Questions Answered in the Cannabinoid Pipeline Insight Report

• Which companies/institutions are leading the Cannabinoid drug development?
• Which company is leading the Cannabinoid pipeline development activities?
• What is the current Cannabinoid commercial assessment?
• What are the opportunities and challenges present in the Cannabinoid pipeline landscape?
• What is the efficacy and safety profile of Cannabinoid pipeline drugs?
• Which company is conducting major trials for Cannabinoid drugs?
• Which companies/institutions are involved in Cannabinoid collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in Cannabinoid?

Reasons To Buy This Report

The Cannabinoid Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for Cannabinoid. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into Cannabinoid collaborations, regulatory environments, and potential growth opportunities.

Related Reports

Clinical Trials Market

Cannabis Beverage Market

Cannabidiol Market

Cannabis Market